IRADIMED CORPORATION— Sankey Diagram
Quarterly mode · period ending 2026-03-31 · SEC EDGAR
ComparingFY2026 (Q4) vs FY2025 (Q4)
Revenue
$22M
↑+12.6% +$2Mvs FY2025 (Q4)
Gross Profit
$17M
↑+13.3% +$2Mvs FY2025 (Q4)
Operating Income
$7M
↑+33.2% +$2Mvs FY2025 (Q4)
Net Income
$6M
↑+24.1% +$1Mvs FY2025 (Q4)
Click a Metric or Sankey Node to View Historical Trends
Show Source Data (Audit Panel)
| Line item | FY2026 (Q4) | FY2025 (Q4) |
|---|---|---|
| Revenue | $22M | $20M |
| COGS | $5M | $5M |
| Gross Profit | $17M | $15M |
| R&D | $956K | $624K |
| SG&A | $0 | $0 |
| D&A | $455K | $194K |
| Other OpEx | $8M | $9M |
| Operating Income | $7M | $5M |
| Interest Exp. | $0 | $0 |
| Other Non-Op | $0 | $0 |
| Pretax Income | $7M | $5M |
| Tax | $1M | $745K |
| Net Income | $6M | $5M |
QuarterCharts · SEC EDGAR data · IRMD · Comparing FY2026 (Q4) vs FY2025 (Q4)